MedTrace Logo

Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine

NCT04921384 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 981

Last updated 2026-01-14

No results posted yet for this study

Summary

This study evaluates the efficacy of eptinezumab to prevent migraine in participants with chronic migraine.

Conditions

Interventions

DRUG

Placebo

0.9% normal saline, intravenously

DRUG

Eptinezumab

Solution for infusion, intravenously

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-29
Primary Completion
2024-10-01
Completion
2025-02-17

Countries

  • China
  • Georgia
  • Japan
  • Poland
  • Slovakia
  • South Korea
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04921384 on ClinicalTrials.gov